This is the first published statement from our MLC consortium, a team of clinical MLC experts. Here, the consortium delves into a recent case report of two MLC patients taking Anakinra. While the original study hinted at positive effects, the experts caution that it is difficult to interpret these results as there is no comparison with kids who did not receive Anakinra and these patients did not show significant or uncharacteristic improvements. Because Anakinra has its risks – daily painful shots and possible side effects – the consortium suggests more research before giving it to MLC patients.
Read paper
